Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: A meta-analysis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Zhi, Xiaofei ^a   Zhou, Xiaoying ^a   Wang, Weizhi ^a   Xu, Zekuan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ARTICLE; CANCER PROGNOSIS; COHORT ANALYSIS; DRUG RESPONSE; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; MUTANT; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; WILD TYPE;

BENZAMIDES; DISEASE-FREE SURVIVAL; EXONS; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; ODDS RATIO; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84892576070     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079275     Document Type: Article

References (34)

1. Bachet JB, Landi B, Laurent-Puig P, Italiano A, Le Cesne A et al. (2013) Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. Eur J Cancer (. (2013)) PubMed: 23648119.
2. Maki RG (2007) Recent advances in therapy for gastrointestinal stromal tumors. Curr Oncol Rep 9: 165-169. doi:10.1007/s11912-007-0017-0. PubMed: 17430686.
3. Miettinen M, Sobin LH, Sarlomo-Rikala M (2000) Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 13: 1134-1142. doi:10.1038/modpathol. 3880210. PubMed: 11048809.
4. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708-710. doi:10.1126/science.1079666. PubMed: 12522257.
5. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121. PubMed: 11719439.
6. Miettinen M, Lasota J (2013) Gastrointestinal stromal tumors. Gastroenterol Clin North Am 42: 399-415. doi:10.1016/j.gtc.2013.01.001. PubMed: 23639648.
7. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D et al. (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307: 1265-1272. doi:10.1001/jama.2012.347. PubMed: 22453568.
8. Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A et al. (2004) Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 202: 430-438. doi:10.1002/path.1546. PubMed: 15095270.
9. Joensuu H, Hohenberger P, Corless CL (2013) Gastrointestinal stromal tumour. Lancet (In press).
10. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M et al. (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349. doi:10.1200/JCO. 2003.04.190. PubMed: 14645423.
11. Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU et al. (2006) Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743-1749. doi: 10.1158/1078-0432.CCR-05-1211. PubMed: 16551858.
12. Kim TW, Ryu MH, Lee H, Sym SJ, Lee JL et al. (2009) Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. Oncologist 14: 540-547. doi:10.1634/theoncologist.2008-0145. PubMed: 19411681.
13. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16. doi:10.1186/1745-6215-8-16. PubMed: 17555582.
14. Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC et al. (2008) Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 26: 5360-5367. doi:10.1200/JCO. 2008.17.4284. PubMed: 18955451.
15. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase. J Clin Oncol: S0033: 26: 626-32
16. Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P et al. (2006) KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42: 1093-1103. doi:10.1016/j.ejca.2006.01.030. PubMed: 16624552.
17. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P et al. (2004) Progression-free survival in gastrointestinal stromal tumours with highdose imatinib: randomised trial. Lancet 364: 1127-1134. doi:10.1016/S0140-6736(04) 17098-0. PubMed: 15451219.
18. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480. doi:10.1056/NEJMoa020461. PubMed: 12181401.
19. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J et al. (2004) Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40: 689-695. doi:10.1016/j.ejca.2003.11.025. PubMed: 15010069.
20. Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S et al. (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39: 2006-2011. doi:10.1016/S0959-8049(02)00836-5. PubMed: 12957454.
21. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423. doi:10.1016/S0140-6736(01)06535-7. PubMed: 11705489.
22. Kang HJ, Ryu MH, Kim KM, Park YS, Choi J et al. (2012) Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study. Acta Oncol 51: 528-536. doi:10.3109/0284186X.2011.636753. PubMed: 22150077.
23. Gao J, Dang Y, Sun N, Li J, Shen L (2012) C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients. Med Oncol 29: 3039-3045. doi: 10.1007/s12032-012-0308-7. PubMed: 22815156.
24. Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC et al. (2007) Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Ann Surg Oncol 14: 1123-1128. doi:10.1245/s10434-006-9288-1. PubMed: 17195905.
25. Rutkowski P, Nowecki ZI, Debiec-Rychter M, Grzesiakowska U, Michej W et al. (2007) Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). J Cancer Res Clin Oncol 133: 589-597. doi: 10.1007/s00432-007-0202-4. PubMed: 17458563.
26. Chen P, Zong L, Zhao W, Shi L (2010) Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: a meta-analysis. World J Gastroenterol 16: 4227-4232. doi:10.3748/wjg.v16.i33.4227. PubMed: 20806443.
27. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM et al. (2004) KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 28: 889-894. doi: 10.1097/00000478-200407000- 00007. PubMed: 15223958.
28. Gounder MM, Maki RG (2011) Molecular basis for primary and secondary tyrosine kinase inhibitor resistance in gastrointestinal stromal tumor. Cancer Chemother Pharmacol 67 Suppl 1: S25-S43. doi:10.1007/s00280-010-1526-3. PubMed: 21116624.
29. Yantiss RK, Rosenberg AE, Sarran L, Besmer P, Antonescu CR (2005) Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol 18: 475-484. doi:10.1038/modpathol. 3800334. PubMed: 15540118.
30. Agaram NP, Wong GC, Guo T, Maki RG, Singer S et al. (2008) Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 47: 853-859. doi:10.1002/gcc.20589. PubMed: 18615679.
31. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC et al. (2012) KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18: 1769-1776. doi: 10.1158/1078-0432.CCR-11- 2230. PubMed: 22282465.
32. Demetri GD, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A et al. (2004) SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol 22 Suppl: 3001.
33. Heinrich MC, Griffith D, McKinley A, Patterson J, Presnell A et al. (2012) Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 18: 4375-4384. doi:10.1158/1078-0432.CCR-12-0625. PubMed: 22745105.
34. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH et al. (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379: 1893-1901. doi:10.1016/S0140-6736(12)60398-5. PubMed: 22608338.